Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Scholar Rock Holding (SRRK – Research Report), Twist...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Scholar Rock Holding (($SRRK)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call of Scholar Rock...

Scholar Rock’s Earnings Call: Optimism Amid Regulatory Challenges

Traders will find all the latest earnings reports, economic data, and deals leading the stock market on Friday.


Market Cap	$4.55B	P/E Ratio	N/A
52W High	$48.28	52W Low	$22.71
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	11.7%	52W Position	94.5%
Overall Score	59	Value Score	40
Quality Score	47	Technical Score	91

EPS Current Est	$-3.4	EPS Next Est	$-3.03
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$46.87	+0.09%	1.93M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRRK	$46.87	+0.1%	1.93M
3
4
5
6

SRRK

SRRK

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Scholar Rock Holding Corporation Data in Excel

Get Scholar Rock Holding Corporation Data in Excel